Management of bipolar I depression: clinical utility of lurasidone

Findlay, Lillian Jan; El-Mallakh, Peggy; El‐Mallakh, Rif S.

doi:10.2147/tcrm.s57695

Cited by 11 publications

(19 citation statements)

References 59 publications

(82 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…38 Maximum concentration increases three-fold when administered with food, indicating that the site of absorption is likely the stomach. 61 In a study aiming to elucidate the target amount of food needed to maximize serum concentration, the mean C max was 52.9 ng/mL in the fasted state, 161 ng/mL for the 350 kcal/high-fat meal, 135 ng/mL for the 500 kcal/high-fat meal, and 131 ng/mL for the 800–1,000 kcal/high-fat meal. 62 Therefore, lurasidone is advised to be taken with about 350 kcal, although fat content per se does not appear to have an influence.…”

Section: The Tolerability and Safety Of Lurasidonementioning

confidence: 99%

Lurasidone for the treatment of bipolar depression: an evidence-based review

Franklin¹,

Zorowitz²,

Corse³

et al. 2015

NDT

View full text Add to dashboard Cite

Bipolar disorder (BD) is a debilitating and difficult-to-treat psychiatric disease that presents a serious burden to patients’ lives as well as health care systems around the world. The essential diagnostic criterion for BD is episodes of mania or hypomania; however, the patients report that the majority of their time is spent in a depressive phase. Current treatment options for this component of BD have yet to achieve satisfactory remission rates. Lurasidone is a drug in the benzisothiazole class approved by the US Food and Drug Administration in June 2013 for the acute treatment of bipolar depression. Its pharmacological profile features high-affinity antagonism at D2, 5-HT2A, and 5-HT7 receptors; moderate-affinity antagonism at α2C-adrenergic receptors; low- to very low-affinity antagonism at α1A-adrenergic, α2A-adrenergic, H1, M1, and 5-HT2C receptors; and high-affinity partial agonism at 5-HT1A. Preliminary findings from two recent double-blinded clinical trials suggest that lurasidone is efficacious in treating bipolar I depression, with clinical effects manifesting as early as the first 2–3 weeks of treatment (as measured by the Montgomery–Åsberg Depression Rating Scale and Clinical Global Impressions Scale for use in bipolar illness). Its therapeutic benefit appears to be comparable to the current US Food and Drug Administration-indicated treatments: quetiapine and olanzapine–fluoxetine, according to a measure of effect size known as number needed to treat. These studies reported relatively limited extrapyramidal and metabolic side effects as a result of treatment with lurasidone, with the most common side effect being nausea. Safety data drawn from these studies, as well as a more extensive body of schizophrenia research, indicate that in comparison with other atypical antipsychotics, treatment with lurasidone is less likely to result in metabolic side effects such as weight gain or disturbances of serum glucose or lipid levels. Lurasidone holds clinical potential as a novel, efficacious pharmacological treatment for bipolar depression. However, current data on its use for the treatment of BD are limited, and more extensive research, both longer in duration as well as independently conducted, is needed.

show abstract

Section: The Tolerability and Safety Of Lurasidonementioning

confidence: 99%

Lurasidone for the treatment of bipolar depression: an evidence-based review

Franklin¹,

Zorowitz²,

Corse³

et al. 2015

NDT

View full text Add to dashboard Cite

show abstract

“…La construction s'élève sur un plan octogonal couronné d'une coupole originellement dotée d'un puits de lumière 19 . Les arcades qui bordent l'espace centré, renvoyant aux thermes romains, sont soutenues par des piliers sur lesquels sont plaqués des ordres anthropomorphes.…”

Section: I Cahier Couleur)unclassified

“…Parmi les actes qui témoignent des travaux réalisés dans le parc de Pratolino à la fin du xviii e siècle, un dossier concernant la grotte de la Samaritaine est particulièrement intéressant 19 Mazzoni, de Vico Fallani, 1986, p. 15 ;Galetto, 2018, p. 258-260. 16.…”

Section: Les Archives Du Scrittoio Delle Fortezze E Fabbricheunclassified

Untitled

2020

artefact

View full text Add to dashboard Cite

The grotto of rockeries designed and built in the middle of the 16 th century in the chateau of La Bâtie d'Urfé is undoubtedly the oldest and most authentic of all those built at the time of the Renaissance in France and Italy. A very complete restoration carried out in 2008 has given back their lustre to all the elements that make it up. Paving, walls adorned with various stone figures and shells, a wooden ceiling decorated with coloured sands, wrought iron grills, marble statues, form a space of profound originality that serves as an atrium for the chapel where human and divine love are united in extreme refinement.

show abstract

“…Bipolar depression is a serious, chronic psychiatric disorder with a lifetime prevalence of approximately 1% worldwide and major adverse consequences such as impairments in cognition, social functioning, and work capacity (1,2). Antipsychotic drugs are treatment of choice for both acute and longterm management of bipolar depression; the most distressing clinical signs and symptoms are managed with the long-term use of antipsychotic medication along with effective psychosocial interventions (3).…”

Section: Introductionmentioning

confidence: 99%

Design, Optimization, and Evaluation of Lurasidone Hydrochloride Nanocrystals

et al. 2015

View full text Add to dashboard Cite

Abstract. The present investigation was carried out to design, optimize, and evaluate lurasidone hydrochloride nanocrystals for improving its solubility and dissolution characteristics. Nanocrystals were prepared by media milling technique using zirconium oxide beads with 0.1 mm diameter. Various stabilizers, viz. poloxamer 188, PVP K30, SLS, HPMC E15, and PVP S 630 D, were evaluated to stabilize the nanocrystals. The Pareto chart obtained through Plackett-Burman screening design revealed that HPMC E 15 showed the highest standardized effect (p value <0.05) on percent dissolution efficiency at 2 min. In subsequent studies, a 3 2 factorial design was employed to quantify the effect of two independent variables, namely amount of stabilizer and milling time on predetermined response variables mean particle size, saturation solubility, and percent dissolution efficiency at 2 min. Statistical analysis of the factorial design revealed that all predetermined response variables were significantly dependent (p value <0.05) on the independent variables. The observed response of the optimized batch prepared as per the desirability function was in close agreement with predicted response, and mathematical model generated was validated. The optimized batch was lyophilized, and X-ray powder diffraction studies indicated that there was no substantial change in crystallinity of the drug. The optimized formulation showed mean particle size of 228 nm and released almost all the drug within first 5 min. Since the crystallinity of the drug is maintained, improvement in saturation solubility and dissolution efficiency could be attributed to decrease in mean particle size of the drug.

show abstract

Management of bipolar I depression: clinical utility of lurasidone

Cited by 11 publications

References 59 publications

Lurasidone for the treatment of bipolar depression: an evidence-based review

Lurasidone for the treatment of bipolar depression: an evidence-based review

Untitled

Design, Optimization, and Evaluation of Lurasidone Hydrochloride Nanocrystals

Contact Info

Product

Resources

About